Anti-Glycan Monoclonal Antibody Development Service

Q: What benefits distinguish Creative Biolabs' Glycan-Targeting mAb Development Service?

We provide niche expertise and cutting-edge platforms (e.g., hybridoma/phage display) that bypass costly internal infrastructure development. Our integrated processes and validated performance history expedite project completion, decrease resource expenditure, and minimize risks in intricate saccharide immunization/screening, yielding accelerated outcomes with enhanced reliability.

Background Anti-Glycan Antibody Published Data What We Can Offer? Why Choose Us? Workflow FAQs Related Products

Precision Antibody Solutions for Glycobiology.

Are you experiencing difficulties targeting precise glycan epitopes for research, diagnostics, or therapeutic applications? Glycan-Specific mAb Development Service at Creative Biolabs expedites discovery and delivers high-specificity immunoreagents via specialized development protocols, large-scale screening systems, and novel glycan modification approaches.

Contact our team to get an inquiry now!

Background

Monoclonal immunoglobulins (mAbs) rank among biology and medicine's most potent and extensively utilized tools, leveraging mammalian immunity's intrinsic self / non-self discrimination. For mAb generation, immunized animals yield splenocytes (e.g., B lymphocytes) that undergo fusion with myeloma cells. Post-fusion, numerous subclones undergo antigen-specificity screening. Following hybridoma line identification, functional characterization precedes manufacturing-scale expansion. To date, thousands of clinically deployed mAbs have undergone multi-purpose characterization. Specifically, glycan-targeting monoclonal antibodies represent ideal cancer therapeutics due to saccharide antigens overexpressed across diverse malignancies.

Anti-Glycan Monoclonal Antibody

Monoclonal immunoglobulins (mAbs) targeting carbohydrate structures are indispensable across fundamental research and clinical domains. These saccharides critically influence cellular functions, including signaling, adhesion, and protein conformation; anti-glycan mAbs enable their detection and functional investigation. Glycans expressed by healthy human cells frequently differ from those on malignant cells, pathogens, or fungi, making disease-specific mAbs particularly clinically significant. Two ganglioside GD2-targeting mAbs have gained regulatory approval as oncological therapeutics, while multiple candidates undergo clinical evaluation, several being extensively employed diagnostically. Advancement of these carbohydrate-targeting immunoglobulins necessitates sophisticated analytical methodologies and comprehensive antibody data access.

Fig.1 Schematic of the human IgG structure and glycan composition. (OA Literature) Fig.1 The human IgG structure and glycan composition.^1,3

Numerous investigations confirm that cell surface glycans critically regulate diverse immunological processes. Understanding these requires generating carbohydrate-targeting antibodies to map spatiotemporal glycan expression patterns. However, monoclonal antibody production against saccharides remains challenging due to endogenous expression of numerous carbohydrate variants in vertebrates. Addressing this, Creative Biolabs engineered an innovative system delivering varied glycan-specific monoclonal immunoglobulins worldwide through bacteriophage display or hybridoma approaches. Leveraging proprietary technology, our carbohydrate-binding reagents detect both glycolipid and glycoprotein targets. Additionally, these immunoreagents serve multiple purposes, including immunohistochemical analysis, cellular staining, adhesion blockade assays, flow cytometric evaluation, enzyme-linked immunosorbent assays, and related biological investigations.

Published Data

Fig 2. Bar Chart showing NEO-201 kills cancer cells expressing core 1 and/or extended core 1 O-glycans through ADCC. (OA Literature) Fig.2 NEO-201 kills cancer cells expressing core 1 and/or extended core 1 O-glycans through ADCC.^2,3

Glycosylation represents a critical post-translational modification affecting mammalian proteins and lipids. Carcinomas display aberrant glycosylation mechanisms, particularly affecting O-glycosylation. Truncated O-glycans manifest in both carcinomas and hematologic malignancies, associated with unfavorable prognoses and oncological progression. Utilizing monoclonal antibodies (mAbs) against shortened O-glycans offers a feasible approach to combat neoplastic growth. Previous studies confirmed humanized IgG1 mAb NEO-201 selectively binds tumor-specific CEACAM5/6 isoforms present in colorectal, ovarian, pancreatic, NSCLC, head/neck, cervical, uterine, and breast cancers, exhibiting negligible cross-reactivity with healthy tissues. Given CEACAMs' extensive glycosylation, this investigation assessed whether NEO-201's epitope constitutes an O-glycan. Our findings reveal NEO-201 recognizes core 1 O-glycans, selectively targeting and eliminating malignant cells expressing core 1 and extended core 1 structures. Since O-glycosylation initiates through GalNAc conjugation to threonine/serine residues, NEO-201 binds these glycans irrespective of carrier proteins containing serine/threonine-rich domains.

What We Can Offer?

Creative Biolabs is a leader in glycan-focused antibody solutions. Having extensive experience in the field of antibody research. Creative Biolabs is proud to offer our clients a series of anti-carbohydrate antibody development services with the best quality and most competitive price.

Our comprehensive offerings include:

Custom Anti-Glycan Monoclonal Antibody Generation: Tailored development of highly specific monoclonal antibodies against a wide range of synthetic and natural glycan targets, including O-glycans, N-glycans, glycolipids, and capsular polysaccharides.
Antibody Characterization Services: Comprehensive biochemical and functional characterization of developed antibodies, including binding affinity, specificity analysis, cross-reactivity profiling, and functional assays relevant to your application.
High-Throughput Glycan Screening: Utilization of advanced platforms for efficient screening of large antibody libraries against diverse glycan arrays, accelerating the discovery of novel binders.
Diagnostic Antibody Development: Expertise in developing anti-glycan antibodies optimized for use in various diagnostic platforms, such as ELISA, lateral flow assays (LFA), and immunohistochemistry.

Experience the Creative Biolabs Advantage - Get a Quote Today

Why Choose Us?

Selecting Creative Biolabs for Glycan-Specific mAb Development secures unmatched proficiency, innovative systems, and dedication to premium outcomes.

Unrivaled Expertise: With over two decades of experience in glycobiology and antibody development, our team of expert biologists possesses deep scientific knowledge essential for navigating the complexities of glycan targets.
Advanced Technological Platforms: We leverage both established hybridoma technology and innovative phage display systems to maximize the diversity and specificity of our antibody candidates, ensuring a comprehensive approach to target challenging glycan epitopes.
Precision and Specificity: Our rigorous screening and validation processes are designed to develop antibodies with exceptional specificity, minimizing off-target binding and providing reliable results for critical applications.
Therapeutic Focus: Capitalizing on field advancements, we excel in developing glycan-targeting immunoreagents for therapeutic use, particularly against refractory malignancies via cancer-specific glycan recognition.
Comprehensive Characterization: Each antibody receives multiparametric validation, guaranteeing functional consistency with project specifications and suitability for intended applications.
Proven Track Record: Our methodologies have consistently delivered high-quality antibodies, supporting diverse research and development initiatives for numerous clients, as evidenced by our Published Data.

Workflow

Fig 3. Workflow of Creative Biolabs service. (Creative Biolabs Original)

FAQs

Here are some frequently asked questions from potential clients interested in Kidney Targeting Module Development:

Q: How does Creative Biolabs guarantee anti-glycan antibody specificity despite prevalent saccharide structural homology?

A: Ensuring antibody specificity constitutes a critical priority at Creative Biolabs. We implement an integrated methodology: initial customized antigen design targeting distinctive glycoepitopes, followed by stringent clone isolation via advanced screening platforms for cross-reactivity assessment. Multi-parametric validation then confirms specificity using glycoarray technology and orthogonal binding comparisons against analogous structures. This systematic workflow delivers immunoreagents with exceptional discriminative binding capacity.

Q: What types of glycan targets can your service accommodate for antibody development?

A: Our platform delivers a comprehensive targeting scope across diverse glycan classes. Targeted structures encompass O-/N-linked glycans, gangliosides, blood group antigens, microbial polysaccharides, and tumor-associated carbohydrate antigens (TACAs), among others. Regardless of target complexity—from elementary to architecturally intricate—our specialists engineer precise immunoreagents against your specified epitopes.

Q: What benefits distinguish Creative Biolabs' Glycan-Targeting mAb Development Service?

A: We provide niche expertise and cutting-edge platforms (e.g., hybridoma/phage display) that bypass costly internal infrastructure development. Our integrated processes and validated performance history expedite project completion, decrease resource expenditure, and minimize risks in intricate saccharide immunization/screening, yielding accelerated outcomes with enhanced reliability.